Nigeria Moves to Extend Pharma Manufacturing Incentives as Government Targets 70% Local Medicine Production

By Simpson Global Media News Desk

The Federal Government is considering a two-year extension of the Presidential Executive Order supporting local pharmaceutical manufacturing, as Nigeria intensifies efforts to reduce dependence on imported medicines and build a more resilient domestic healthcare supply chain.

The proposed extension would take the current policy window beyond its expected March 2027 expiration and give manufacturers additional time to invest in factories, production equipment, active pharmaceutical ingredients and other parts of the medicine supply chain.

The development emerged from the 8th Nigeria Pharmaceutical Manufacturers Expo, held in Lagos, where manufacturers, regulators, government officials, investors and development partners examined the future of medicine production in Nigeria.

The Federal Government has set a target of achieving at least 70 per cent domestic production of essential healthcare products by 2030. It says the objective is to strengthen medicine security, reduce vulnerability to international supply disruptions and develop Nigeria into a pharmaceutical manufacturing hub for West Africa and the wider African market.

The Pharmaceutical Manufacturers Group of the Manufacturers Association of Nigeria, PMGMAN, has welcomed the direction but wants the incentives underpinning the current manufacturing push to remain in place.

The group says continuity is important because pharmaceutical production requires substantial long-term investment, while manufacturers are still dealing with high energy costs, supply-chain difficulties, port inefficiencies, limited access to long-term financing and challenges in reaching larger markets.

The government says its policy approach is intended to address some of those structural problems through tax and tariff relief, financing initiatives, procurement reforms, regulatory measures and support for production across the pharmaceutical value chain.

The debate over extending the Executive Order is consequently becoming an important part of Nigeria's wider health-security strategy.

Why Local Medicine Production Matters

Nigeria has a large population and a substantial demand for medicines, vaccines, diagnostics and other healthcare products.

For years, however, much of that demand has depended on imports.

At the 2026 pharmaceutical manufacturers' expo, industry representatives said roughly 70 per cent of medicines consumed in Nigeria had historically been imported, with domestic manufacturers supplying about 30 per cent.

That imbalance creates vulnerabilities when international supply chains are disrupted, foreign exchange conditions change or the cost of imported inputs rises.

The COVID-19 pandemic demonstrated how quickly global supply chains can become unreliable during a major health emergency.

Countries around the world competed for medicines, medical equipment, vaccines and raw materials.

For Nigeria, the experience reinforced the importance of having greater domestic manufacturing capability.

The Federal Ministry of Health and Social Welfare has therefore described local pharmaceutical production as part of national resilience rather than simply an industrial policy.

Minister of State for Health and Social Welfare Iziaq Salako said disruptions during the COVID-19 pandemic and changes in global healthcare financing had demonstrated the need for Nigeria and other African countries to develop stronger domestic capacity to produce medicines, vaccines, diagnostics and critical health technologies.

That argument extends beyond having factories that package finished medicines.

A resilient pharmaceutical sector requires access to raw materials, active pharmaceutical ingredients, formulation technology, quality-control systems, skilled personnel, financing, reliable electricity, logistics and functioning distribution networks.

The government is now attempting to develop several of those components simultaneously.

The Executive Order at the Centre of the Debate

The current pharmaceutical manufacturing policy framework dates to an Executive Order issued in October 2024.

The official Presidential Initiative to Unlock the Healthcare Value Chain says the order was designed to address underinvestment, weak policy implementation and regulatory challenges affecting local production.

The order introduced fiscal and non-fiscal incentives intended to make domestic pharmaceutical manufacturing more competitive.

Among the measures are zero tariffs and excise duties on specified pharmaceutical machinery, equipment, goods and accessories.

The framework also provides special waivers covering active pharmaceutical ingredients, excipients and other raw materials used in the production of essential medicines and medical products.

Other provisions seek to support domestic manufacturers through framework contracts and volume guarantees, while regulatory harmonisation and expedited approval processes are intended to reduce some of the administrative barriers associated with manufacturing and market entry.

The current policy window was designed to run for two years from its effective date.

With that period approaching its scheduled end, pharmaceutical manufacturers are asking the government to extend it.

PMGMAN Chairman Oluwatosin Jolayemi said the sector needs policy continuity to deepen investments and expand production capacity.

The manufacturers' position is that investors need confidence that fiscal and regulatory conditions will remain sufficiently stable for long-term projects to become viable.

Government Signals Two-Year Extension

The Federal Government has now indicated that it plans to extend the Executive Order for another two years.

The announcement was reported after the 8th Nigeria Pharmaceutical Manufacturers Expo in Lagos.

The current policy window is expected to expire in March 2027, while the proposed extension would take it to 2029.

The proposed continuation does not mean all problems confronting the industry have been resolved.

Manufacturers continue to face production costs that can make locally produced medicines less competitive.

Electricity remains a major consideration for pharmaceutical factories because production and quality-control processes require reliable power.

Manufacturers also depend on imported inputs for significant parts of the production chain.

Foreign exchange movements can therefore affect the cost of active ingredients, machinery, packaging materials and other supplies.

The government is attempting to address some of those pressures by promoting domestic production of ingredients and encouraging investments further upstream.

70 Per Cent Local Production Target

The Federal Government's longer-term objective is to achieve at least 70 per cent local production of essential healthcare products by 2030.

That target covers more than conventional finished medicines.

Government plans include greater domestic capacity for pharmaceuticals, vaccines, biologics, diagnostics and other critical health products.

The Presidential Initiative to Unlock the Healthcare Value Chain says domestic manufacturing is one of its principal objectives and is intended to reduce import dependence while strengthening national resilience.

At the September 2026 pharmaceutical manufacturers' expo, Salako said the Presidential Initiative to Unlock the Healthcare Value Chain had secured financing commitments of approximately $2 billion at single-digit interest rates.

About 50 Nigerian health companies were said to be in advanced discussions for financing under the initiative.

The government also reported that 87 local manufacturers were benefiting from the pharmaceutical Executive Order, including tariff relief covering pharmaceutical machinery, active pharmaceutical ingredients and excipients across almost 1,000 Harmonised System codes.

If implemented effectively, such measures could lower some of the capital and input costs associated with local production.

But the scale of the 70 per cent target means that production capacity will have to expand substantially.

From Finished Medicines to Active Ingredients

One of the most important aspects of the government's strategy is the effort to move beyond simply manufacturing finished medicines from imported ingredients.

Active pharmaceutical ingredients, or APIs, are the substances responsible for the therapeutic effect of medicines.

If Nigerian factories continue to import most of their APIs, the country would remain vulnerable to disruptions elsewhere in the supply chain even if the final tablets, capsules or syrups are produced locally.

The Federal Ministry of Health has therefore highlighted plans to increase local API production.

It has pointed to the operationalisation of the NIPRD API Capacity Building and Concept Production Centre and efforts to develop commercial-scale API manufacturing capacity.

The government has also highlighted initiatives to localise production of diagnostics for HIV, hepatitis and syphilis.

The aim is to create a broader ecosystem in which research, raw materials, manufacturing, quality assurance and distribution become increasingly connected within Nigeria and the wider African market.

That is a considerably more demanding objective than increasing the number of factories producing finished medicines.

Research and Development Becomes Central

The pharmaceutical sector also depends on research.

The Federal Government has called for greater investment in research and development, including research into Nigeria's phytomedicinal resources.

The Ministry has argued that genuine localisation should not mean importing active ingredients, packaging materials and technologies and simply assembling finished products in Nigeria.

Instead, the objective is to progressively build capability across the entire value chain, from research and raw materials through formulation, quality assurance, manufacturing, packaging and distribution.

That approach could have implications for universities, research institutions and pharmaceutical companies.

Research institutions could become more closely connected to industrial production.

Companies could require stronger partnerships with universities and laboratories.

The country's pharmaceutical scientists and engineers could have greater opportunities to participate in the development of new formulations, manufacturing processes and quality-control technologies.

But such an ecosystem requires sustained financing.

Research projects often take years before they produce commercially viable results.

The availability of long-term funding is therefore likely to remain a major factor in whether Nigeria can develop a deeper pharmaceutical manufacturing base.

Financing the Healthcare Value Chain

The government's $2 billion financing commitment under PVAC is one component of the strategy.

According to the Federal Ministry of Health, the financing is intended to support Nigerian health companies at relatively favourable interest rates.

About 50 firms were reported to be in advanced funding discussions at the time of the September expo.

Access to long-term capital is important because pharmaceutical manufacturing facilities require substantial upfront investment.

A company may need to purchase specialised production equipment, construct controlled manufacturing environments, install quality-control laboratories, secure regulatory approvals and develop storage and distribution systems before production can reach commercially sustainable volumes.

Financing must therefore be sufficiently long-term and predictable to match the investment cycle.

Manufacturers have repeatedly identified access to long-term capital as one of the obstacles facing the sector.

The proposed continuation of the Executive Order is intended to operate alongside financing initiatives rather than substitute for them.

Energy Costs Remain a Major Challenge

Policy incentives alone cannot determine the competitiveness of Nigerian pharmaceutical manufacturers.

Energy costs remain a significant concern.

Pharmaceutical production requires controlled environments, machinery, refrigeration in some areas, laboratories, water treatment and other systems that depend on reliable electricity.

Where grid supply is inadequate, manufacturers may have to rely on alternative sources of power.

That increases operating costs.

PMGMAN has identified high energy and production costs among the challenges facing local manufacturers.

The group has also pointed to supply-chain difficulties, port inefficiencies, limited access to long-term capital and market-access constraints.

These challenges matter because a medicine manufactured locally still has to compete on price with imported products.

If domestic production becomes substantially more expensive, manufacturers may struggle to gain market share even when government policy favours local products.

That is why the pharmaceutical industry's request for continued incentives is accompanied by calls for broader reforms.

Port and Logistics Problems

Nigeria's pharmaceutical supply chain also depends on efficient logistics.

Even when a medicine is manufactured domestically, manufacturers may still need to import certain raw materials, machinery or specialised components.

Delays at ports can increase costs and disrupt production schedules.

Imported ingredients may have to undergo customs procedures, quality checks and transportation to factories.

Finished medicines then have to move through distribution networks to wholesalers, pharmacies, hospitals and other healthcare providers.

A disruption at any point can affect availability.

Manufacturers have therefore called for improvements in port operations and supply-chain efficiency.

For medicine security, the objective is not simply to increase factory capacity.

The entire chain from raw material to patient has to function reliably.

NAFDAC's Regulatory Role

The National Agency for Food and Drug Administration and Control, NAFDAC, remains central to the local manufacturing drive.

Domestic production can only strengthen health security if medicines meet appropriate quality and safety standards.

NAFDAC Director-General Professor Mojisola Adeyeye said 37 local manufacturing facilities were undergoing retrofitting and construction upgrades to meet international standards.

The agency has also continued efforts towards WHO global benchmarking and stronger enforcement against facilities that fail to comply with regulatory requirements.

Regulation therefore forms a second side of the manufacturing strategy.

Nigeria wants more medicines produced domestically, but the expansion has to occur alongside quality assurance.

Poor-quality or substandard medicines could create significant public-health consequences.

A stronger manufacturing base must consequently be accompanied by robust inspections, testing, surveillance and enforcement.

NAFDAC's 5+5 Policy

The regulator has also pointed to the contribution of its 5+5 policy to local pharmaceutical production.

The policy is designed to create incentives and regulatory conditions that encourage manufacturers to maintain or increase domestic production.

NAFDAC said reforms under the 5+5 framework had contributed to reducing drug importation while encouraging local manufacturers to improve standards.

The agency has stressed that Nigeria cannot afford to reverse progress made in local pharmaceutical manufacturing.

At the same time, it has called for greater attention to vaccines and other critical health commodities.

The combination of regulatory standards and manufacturing incentives will be important if Nigeria wants to supply both its domestic market and other African countries.

The Role of Medipool

Another component of the government's strategy is Medipool, described by the Ministry of Health as Nigeria's national Group Purchasing Organisation for essential medicines and medical commodities.

The system is intended to aggregate procurement, negotiate bulk purchases and create more predictable demand for domestic manufacturers.

Predictable demand can be important for manufacturers considering investments in new production capacity.

A factory is more likely to justify substantial investment if there is confidence that sufficient quantities of its products can be sold.

Government and institutional procurement can therefore help create a market for locally manufactured medicines.

The Ministry says Medipool is intended to improve supply-chain efficiency while creating predictable and large-scale demand for domestic manufacturers.

The effectiveness of the model will depend on how procurement is structured, how quickly payments are made and how successfully manufacturers meet quality and delivery requirements.

Medicine Prices and Patients

For ordinary Nigerians, the most important question is how these industrial policies affect access to medicines.

Local manufacturing could potentially reduce exposure to foreign exchange volatility and international shipping costs.

It could also shorten parts of the supply chain and improve the ability of manufacturers to respond to domestic demand.

However, local production does not automatically mean lower prices.

Manufacturers still face costs associated with energy, labour, financing, raw materials, quality control, distribution and regulatory compliance.

If those costs remain high, domestically manufactured medicines may not become substantially cheaper simply because they are produced inside Nigeria.

The government's strategy therefore combines production incentives with efforts to address the wider health value chain.

The ultimate test will be whether increased domestic capacity contributes to reliable availability and more sustainable access to essential medicines.

Medicine Security and Public Health

Medicine security has become an increasingly important concept in global health policy.

A country is vulnerable when its essential medicines depend heavily on external suppliers and international supply chains.

During normal conditions, imports can provide access to a broad range of medicines.

During crises, however, suppliers may prioritise their domestic markets or face their own production shortages.

Nigeria's strategy is partly intended to reduce that vulnerability.

The Federal Ministry of Health has explicitly linked local pharmaceutical production with medicine security and healthcare resilience.

That approach became particularly visible during the COVID-19 pandemic, when international restrictions and supply-chain disruptions affected access to medical products in many countries.

The lesson for policymakers is that domestic production capacity can have strategic value even when imports remain an important part of the market.

Vaccines and Biologics

The manufacturing strategy extends beyond conventional medicines.

The Federal Government has highlighted the need to develop domestic capacity for vaccines, biologics and diagnostics.

These products can be more technically demanding than many conventional pharmaceutical formulations.

They require specialised facilities, highly trained personnel, advanced quality-control systems and regulatory expertise.

Building those capabilities could take years.

The government is therefore treating them as part of a longer-term pharmaceutical industrialisation strategy rather than a short-term manufacturing target.

Salako has called for investment in sophisticated areas of production, including biologics, vaccines and other critical health technologies.

The emphasis is particularly relevant to pandemic preparedness.

A country that can manufacture some critical vaccines, diagnostics and therapeutic products domestically may be better positioned to respond to future outbreaks.

However, developing that capability requires sustained investment and strong regulatory systems.

Nigeria and the African Market

The government also sees pharmaceutical manufacturing as an export opportunity.

Nigeria's large domestic market provides a substantial base for manufacturers, but the African Continental Free Trade Area could potentially give companies access to a much wider market.

Government officials have encouraged manufacturers to use AfCFTA to expand across Africa.

The objective is to move from a market focused primarily on domestic consumption towards a regional manufacturing ecosystem.

That ambition would require Nigerian manufacturers to meet international quality standards and compete on cost.

Regulatory differences between African countries can also create barriers.

The African Medicines Agency has therefore called for stronger regulatory cooperation across the continent.

Its Director-General, Dr Delese Mimi Darko, said regulatory harmonisation could help manufacturers navigate African markets more efficiently and encourage investment in research, technology transfer, skilled manpower, intellectual property and quality systems.

Regional Regulatory Harmonisation

A pharmaceutical company seeking to sell products across multiple African markets can face separate regulatory requirements in each country.

That can increase the time and cost involved in registration.

Greater harmonisation could reduce duplication and make it easier for manufacturers to expand.

For Nigeria, regional regulatory cooperation could therefore strengthen the value of investments being made domestically.

A factory capable of producing high-quality medicines for Nigeria could potentially become a supplier to other African countries.

But that possibility depends on meeting the regulatory requirements of those markets.

It also depends on reliable transportation and distribution infrastructure.

More Than 200 Local Manufacturers

The PMGMAN says it now represents more than 200 local pharmaceutical manufacturing companies.

The group has grown considerably from its earlier membership base and says the sector is undergoing significant transformation.

The number of companies alone, however, does not measure the strength of the industry.

What matters is the scale and quality of their production, the range of medicines manufactured locally, the proportion of inputs sourced domestically, their ability to meet regulatory standards and their capacity to compete in regional markets.

The government's target of 70 per cent local production is therefore a measure of production depth as well as factory numbers.

It requires domestic manufacturers to move into increasingly sophisticated areas of production.

Industry Self-Regulation

PMGMAN also unveiled an Industry Self-Regulation Quality Plus Project at the 2026 expo.

The programme includes a five-year Medicine Security Industry Advocacy Strategy covering 2027 to 2031.

The group also announced plans for an industry laboratory and a Data Repository and Learning Centre.

According to the reported plans, the different components are expected to be commissioned progressively within the next six to 10 months.

The initiative reflects the industry's effort to build additional quality and information systems alongside government regulation.

Industry self-regulation does not replace statutory oversight by NAFDAC.

Rather, it can provide manufacturers with mechanisms for improving internal standards, collecting industry information and identifying areas where common problems require coordinated action.

The Importance of Skilled Workers

Expanding pharmaceutical manufacturing will also require more skilled personnel.

Factories need pharmacists, chemists, microbiologists, engineers, laboratory specialists, quality-assurance professionals, regulatory experts and technicians.

As production moves into APIs, vaccines, biologics and other advanced products, the demand for specialised skills will increase.

The development of such skills creates opportunities for Nigerian universities and technical institutions to strengthen programmes linked to pharmaceutical science, biotechnology, engineering and manufacturing.

It could also reduce reliance on imported expertise.

However, retaining skilled workers will be important.

Nigeria's broader health sector has experienced substantial movement of trained professionals to other countries.

A growing pharmaceutical manufacturing industry would need competitive working conditions and career opportunities to retain expertise.

What the Extension Could Mean for Manufacturers

If the Executive Order is extended, manufacturers would gain additional time under the existing incentive framework.

That could influence investment decisions already under consideration.

Companies may be more willing to expand factories, purchase machinery or enter new production areas if they have greater certainty about tariffs and other fiscal measures.

The government would also have more time to evaluate which elements of the current policy are delivering results and which require adjustment.

An extension, however, would not remove the need for structural reforms.

Manufacturers are asking for continued support on energy, financing, logistics and market access.

The policy challenge is therefore to combine temporary incentives with reforms that improve the industry's long-term competitiveness.

The Need for Policy Consistency

Manufacturing investments typically take years to recover.

Pharmaceutical factories are particularly sensitive to regulatory and quality requirements.

A company can spend substantial sums building a facility and obtaining approvals before reaching full production.

Sudden changes in tariffs, taxes, procurement rules or regulatory requirements can affect the commercial calculations behind such investments.

That is why manufacturers are asking for policy continuity.

PMGMAN says a predictable investment environment is necessary to deepen investments and consolidate gains already made.

From the government's perspective, continued incentives must also produce measurable results.

If fiscal concessions are extended, policymakers will need to assess whether they are translating into increased domestic capacity, higher production volumes, greater employment, stronger quality standards and improved availability of essential medicines.

Beyond Import Substitution

The government's ambition goes beyond replacing imported medicines with Nigerian-made alternatives.

Officials are increasingly describing the goal as developing a regional pharmaceutical manufacturing industry.

That means creating companies capable of producing medicines at sufficient scale and quality to serve Nigeria and other African markets.

It also means developing domestic capabilities in research, raw materials, technology, quality assurance and regulation.

The Ministry has described this as moving from dependency to capability and from fragmented markets to regional scale.

Such a transformation would take time.

But the policy decisions being made now will influence whether Nigeria's pharmaceutical industry remains largely dependent on imported inputs or develops deeper domestic production capacity.

Challenges That Remain

Despite the policy support, significant challenges remain.

Energy costs can affect production economics.

Foreign exchange fluctuations can raise the cost of imported inputs.

Ports and logistics can create delays.

Long-term financing remains difficult for many manufacturers.

Research and development require sustained investment.

Regulatory approval and compliance can be costly.

Regional markets have different requirements.

Skilled personnel must be recruited and retained.

And local manufacturers must compete with established international pharmaceutical companies.

The 70 per cent target therefore represents a major industrial and health-system challenge.

Achieving it will require coordination across several government ministries and agencies, private manufacturers, financial institutions, research organisations, regulators and development partners.

Government's Broader Health-Industry Strategy

The pharmaceutical manufacturing drive forms part of a broader effort to strengthen Nigeria's healthcare value chain.

The Presidential Initiative to Unlock the Healthcare Value Chain identifies domestic manufacturing of pharmaceuticals, vaccines, biologics, medical consumables and devices as a central objective.

It also aims to support quality jobs and reduce medical tourism by strengthening domestic healthcare capacity.

The approach therefore connects manufacturing with wider healthcare development.

A stronger pharmaceutical industry can create industrial jobs and technical skills.

Research and manufacturing partnerships can support innovation.

Domestic production can improve supply resilience.

And a larger health-industrial base can create opportunities for exports.

The results, however, will depend on implementation.

What Happens Next

The immediate next step is the government's consideration and implementation of the proposed extension of the pharmaceutical Executive Order.

The current policy window is expected to expire in March 2027.

Manufacturers want the extension to run for another two years, while government officials have indicated support for continued policy measures aimed at strengthening local production.

The industry will also be watching the implementation of financing commitments under PVAC.

The reported $2 billion financing commitments and advanced discussions with approximately 50 health firms could provide additional capital for manufacturing expansion if the funding is successfully deployed.

NAFDAC's work to upgrade manufacturing facilities and improve regulatory compliance will remain another important part of the process.

The government is also expected to continue developing local capacity for APIs, vaccines, biologics and diagnostics.

Measuring Whether the Strategy Works

The success of the policy will ultimately need to be measured against practical outcomes.

Those outcomes include how much of Nigeria's essential medicines are manufactured domestically.

They include whether the quality of locally manufactured medicines improves and remains consistently compliant with regulatory standards.

They include whether manufacturing capacity expands beyond finished-dose products into APIs and other critical inputs.

They include whether medicine shortages become less vulnerable to international supply disruptions.

And they include whether patients can obtain essential medicines reliably and at sustainable prices.

The 70 per cent target provides a broad benchmark, but progress will need to be assessed across individual categories of medicines and healthcare products.

Medicine Security as a Long-Term Project

Nigeria's push for pharmaceutical self-reliance is unlikely to be completed through one Executive Order or a single investment programme.

The sector requires a long-term industrial strategy.

The current Executive Order can provide fiscal incentives, but competitive production also depends on infrastructure, financing, skilled labour, research, regulation and access to markets.

Similarly, local production cannot completely eliminate the need for imports.

Some medicines and specialised ingredients may continue to come from international suppliers.

The objective is to reduce excessive dependence while ensuring that Nigeria can produce a larger proportion of critical healthcare products when global supply chains are disrupted.

That balance is important because complete self-sufficiency in every pharmaceutical product would be difficult and potentially inefficient.

A resilient system is more likely to combine strong domestic capacity with diversified international supply relationships.

A Potential Turning Point for Nigerian Pharma

The current policy discussion comes at a significant moment for Nigeria's pharmaceutical sector.

The country has a large domestic market, an expanding manufacturing base and a government that has placed medicine security on the national health agenda.

The proposed extension of the Executive Order could give manufacturers additional time to make investments under a relatively supportive policy environment.

At the same time, the government's 2030 target sets a demanding benchmark.

The industry must increase production while dealing with high costs and infrastructure constraints.

Regulators must maintain quality standards while supporting efficient approval processes.

Financial institutions must find ways to provide longer-term capital.

Research institutions must connect more closely with industry.

And regional regulators must continue efforts to make African markets more accessible to manufacturers.

Conclusion

Nigeria is moving to extend its pharmaceutical manufacturing incentives as the Federal Government seeks to build a stronger domestic medicine industry and reduce the country's dependence on imported healthcare products.

The government has indicated plans to extend the Presidential Executive Order supporting local pharmaceutical production by another two years, potentially taking the current policy framework beyond its expected March 2027 expiration.

The move follows renewed calls from pharmaceutical manufacturers for policy continuity.

Industry leaders argue that additional time under the incentives would help companies deepen investments, expand capacity and consolidate progress already made.

The government, meanwhile, is targeting at least 70 per cent local production of essential healthcare products by 2030 and has reported about $2 billion in financing commitments under its Presidential Initiative to Unlock the Healthcare Value Chain.

The strategy extends beyond finished medicines.

Nigeria is seeking greater domestic production of active pharmaceutical ingredients, vaccines, biologics, diagnostics and other critical health technologies.

The Federal Ministry of Health has also emphasised research and development, including efforts to develop pharmaceutical capabilities around locally available resources.

NAFDAC is playing a central role by strengthening regulatory oversight and supporting improvements in manufacturing facilities.

The agency says 37 local manufacturing facilities are undergoing retrofitting and construction upgrades to meet international standards, while regulatory reforms are being used to support domestic production and maintain quality.

Yet the road to medicine security remains challenging.

Manufacturers continue to face high energy and production costs, supply-chain difficulties, port inefficiencies, limited access to long-term financing and market-access barriers.

Those issues mean that extending fiscal incentives alone will not be sufficient to transform the sector.

Nigeria will also need reliable infrastructure, stronger research capacity, efficient regulation, skilled workers, accessible financing and effective procurement systems.

The government's Medipool initiative is intended to create more predictable demand for domestic manufacturers by aggregating procurement and negotiating bulk purchases, while regional regulatory cooperation is expected to help Nigerian companies access wider African markets.

The potential extension of the Executive Order therefore represents one part of a much larger health and industrial strategy.

If the measures are implemented consistently, they could provide manufacturers with greater certainty to invest in production.

But the eventual measure of success will be what happens beyond the factories and policy documents.

For patients, medicine security means being able to find essential medicines when they need them.

For healthcare providers, it means more reliable supplies.

For manufacturers, it means an environment in which investment and production can remain commercially viable.

For government, it means reducing vulnerabilities exposed by international supply disruptions while building a competitive health-industrial sector.

And for Nigeria's wider economy, a stronger pharmaceutical industry could create jobs, develop technical skills, support research and open opportunities for exports across Africa.

The proposed two-year extension gives policymakers and manufacturers additional time to pursue those objectives.

The next phase will show whether the country's incentives, investments and reforms can translate into sustained increases in domestic pharmaceutical capacity.

For now, the direction is clear: Nigeria is seeking to move from heavy reliance on imported medicines towards a health system with a deeper domestic manufacturing base, stronger supply-chain resilience and greater capacity to produce critical healthcare products within the country.